BioCentury | Nov 5, 2012
Finance

Skyline's limit

Skyline's limit Skyline Ventures isn't talking about its decision to suspend fundraising for a sixth fund, but its performance compared to other healthcare VCs shows just how hard it is to raise money these days....
BC Extra | Aug 17, 2012
Company News

Sophiris names Woods CEO

Sophiris Bio Inc. (TSX:SHS) hired Randall Woods as CEO. Woods is the former president and CEO of NovaCardia Inc. , which Merck & Co. Inc. (NYSE:MRK) acquired in 2007. Sophiris (formerly Protox Therapeutics Inc. ) is developing...
BC Week In Review | Apr 23, 2012
Company News

Sorbent board of directors update

Sorbent Therapeutics Inc. , Sunnyvale, Calif.   Business: Renal, Cardiovascular   Appointed: Randall Woods, formerly president and CEO of NovaCardia Inc. , which Merck & Co. Inc. acquired, as chairman  ...
BC Week In Review | Oct 18, 2010
Clinical News

Rolofylline: Additional Phase III data

Additional data from the double-blind, international Phase III PROTECT trial in 2,033 patients showed that 30 mg/day IV rolofylline for up to 3 days led to persistent renal impairment in 15% of patients vs. 13.7%...
BC Week In Review | Aug 10, 2009
Clinical News

Rolofylline: Development discontinued

Merck discontinued development of rolofylline after announcing in June that the compound missed the primary and secondary endpoints in the international Phase III PROTECT trial (see BioCentury, June 8). Merck gained rolofylline through its acquisition...
BC Week In Review | Jun 8, 2009
Clinical News

Rolofylline: Preliminary Phase III data

Preliminary data from the double-blind, placebo-controlled, international Phase III PROTECT trial in 2,033 patients showed that 30 mg IV rolofylline missed the primary endpoint of improving symptoms of AHF compared with placebo. The trial also...
BC Extra | Jun 6, 2009
Clinical News

Merck's rolofylline misses heart failure endpoint

Merck & Co. Inc. (NYSE:MRK) said preliminary data from the Phase III PROTECT trial showed that 30 mg IV rolofylline missed the primary endpoint of improving symptoms of acute heart failure compared to placebo. The...
BC Week In Review | Apr 7, 2008
Clinical News

Rolofylline: Phase III data

Additional data from a double-blind Phase III trial in 301 patients with acute CHF and renal impairment showed that the highest dose of rolofylline (30 mg) produced a 53% rate of treatment success vs. a...
BioCentury | Jan 14, 2008
Finance

2008 Financial Markets Preview: Looking for an oasis

The first quarter is usually a time of plenty for biotech, but this year market watchers are worried that 1Q08 - and indeed the entire first half - may be lackluster when it comes to financing and...
BioCentury | Jan 7, 2008
Finance

Ebb & Flow

Making bets on expanding waistlines and receding hairlines, last week PureTech Ventures put more money in two early stage companies it had helped found: obesity play Gelesis and hair loss prevention company Follica . In both...
Items per page:
1 - 10 of 44
BioCentury | Nov 5, 2012
Finance

Skyline's limit

Skyline's limit Skyline Ventures isn't talking about its decision to suspend fundraising for a sixth fund, but its performance compared to other healthcare VCs shows just how hard it is to raise money these days....
BC Extra | Aug 17, 2012
Company News

Sophiris names Woods CEO

Sophiris Bio Inc. (TSX:SHS) hired Randall Woods as CEO. Woods is the former president and CEO of NovaCardia Inc. , which Merck & Co. Inc. (NYSE:MRK) acquired in 2007. Sophiris (formerly Protox Therapeutics Inc. ) is developing...
BC Week In Review | Apr 23, 2012
Company News

Sorbent board of directors update

Sorbent Therapeutics Inc. , Sunnyvale, Calif.   Business: Renal, Cardiovascular   Appointed: Randall Woods, formerly president and CEO of NovaCardia Inc. , which Merck & Co. Inc. acquired, as chairman  ...
BC Week In Review | Oct 18, 2010
Clinical News

Rolofylline: Additional Phase III data

Additional data from the double-blind, international Phase III PROTECT trial in 2,033 patients showed that 30 mg/day IV rolofylline for up to 3 days led to persistent renal impairment in 15% of patients vs. 13.7%...
BC Week In Review | Aug 10, 2009
Clinical News

Rolofylline: Development discontinued

Merck discontinued development of rolofylline after announcing in June that the compound missed the primary and secondary endpoints in the international Phase III PROTECT trial (see BioCentury, June 8). Merck gained rolofylline through its acquisition...
BC Week In Review | Jun 8, 2009
Clinical News

Rolofylline: Preliminary Phase III data

Preliminary data from the double-blind, placebo-controlled, international Phase III PROTECT trial in 2,033 patients showed that 30 mg IV rolofylline missed the primary endpoint of improving symptoms of AHF compared with placebo. The trial also...
BC Extra | Jun 6, 2009
Clinical News

Merck's rolofylline misses heart failure endpoint

Merck & Co. Inc. (NYSE:MRK) said preliminary data from the Phase III PROTECT trial showed that 30 mg IV rolofylline missed the primary endpoint of improving symptoms of acute heart failure compared to placebo. The...
BC Week In Review | Apr 7, 2008
Clinical News

Rolofylline: Phase III data

Additional data from a double-blind Phase III trial in 301 patients with acute CHF and renal impairment showed that the highest dose of rolofylline (30 mg) produced a 53% rate of treatment success vs. a...
BioCentury | Jan 14, 2008
Finance

2008 Financial Markets Preview: Looking for an oasis

The first quarter is usually a time of plenty for biotech, but this year market watchers are worried that 1Q08 - and indeed the entire first half - may be lackluster when it comes to financing and...
BioCentury | Jan 7, 2008
Finance

Ebb & Flow

Making bets on expanding waistlines and receding hairlines, last week PureTech Ventures put more money in two early stage companies it had helped found: obesity play Gelesis and hair loss prevention company Follica . In both...
Items per page:
1 - 10 of 44